Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke In International Journal of Stroke 0(0) 1–8, published on May, 2016 Authors Isuru Induruwa1, Stephanie M Jung2 and Elizabeth A Warburton1 Abstract Background: Platelets are essential to physiological hemostasis or pathological thrombus formation. Current antiplate- let agents inhibit platelet aggregation but leave patients at risk of systemic […]

Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials In Lancet 2016; 387: 1723–31, published on February 18, 2016 Authors Mayank Goyal, Bijoy K Menon, Wim H van Zwam, Diederik W J Dippel, Peter J Mitchell, Andrew M Demchuk, Antoni Dávalos, Charles B L M Majoie, Aad van der Lugt, […]

Antiplatelet drugs: which targets for which treatments? In Journal of Thrombosis and Haemostasis, 13 (Suppl. 1): S313–S322, 2015 Authors Christian Gachet Abstract The current standard care for acute coronary syndromes is dual antiplatelet therapy combining the COX1 inhibitor aspirin with a drug targeting the P2Y12 receptor, together with anticoagulation during and after early revascularization by percutaneous […]

Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation In Blood. 2015 Jul 30;126(5):683-91 – Published on July 30, 2015 Authors Mammadova-Bach E, Ollivier V, Loyau S, Schaff M, Dumont B, Favier R, Freyburger G, Latger-Cannard V, Nieswandt B, Gachet C, Mangin PH, Jandrot-Perrus M. Abstract Fibrin, the coagulation end product, consolidates the […]

A Humanized Glycoprotein VI (GPVI) Mouse Model to Assess the Antithrombotic Efficacies of Anti-GPVI Agents In Journal of Pharmacology and Experimental Therapeutics April 2012, 341 (1) 156-163, published on April 2012 Authors Pierre Henri Mangin, ChaoJun Tang, Catherine Bourdon, Stéphane Loyau, Monique Freund, Béatrice Hechler, Christian Gachet, and Martine Jandrot-Perrus Asbtract Glycoprotein VI (GPVI) has been […]